Effects of chronic masitinib treatment in APPPS1dE9 transgenic mice modeling Alzheimer’s disease - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Journal of Alzheimer's Disease Année : 2020

Effects of chronic masitinib treatment in APPPS1dE9 transgenic mice modeling Alzheimer’s disease

Ihsen Youssef
  • Fonction : Auteur
  • PersonId : 779180
  • IdRef : 135601126

Résumé

Background: Masitinib is a selective tyrosine kinase inhibitor that modulates mast cells activity. A previous phase II study reported a cognitive effect of masitinib in patients with Alzheimer's disease. Objective: We aimed to shed light on the mode of action of masitinib in Alzheimer's disease. Methods/Results: We demonstrated here that chronic oral treatment of APPswe/PSEN1dE9 transgenic mice modeling Alzheimer's disease restored normal spatial learning performance while having no impacts on amyloid-␤ loads nor on neuroinflammation. However, masitinib promoted a recovery of synaptic markers. Complete genetic depletion of mast cells in APPswe/PSEN1dE9 mice similarly rescued synaptic impairments. Conclusion: These results underline that masitinib therapeutic efficacy might primarily be associated with a synaptoprotective action in relation with mast cells inhibition.
Fichier principal
Vignette du fichier
2020BDelatour_Effects of chronic.pdf (2.58 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03035522 , version 1 (25-05-2021)

Identifiants

Citer

Tengfei Li, Elodie Martin, Yah-Se Abada, Céline Boucher, Aurélia Cès, et al.. Effects of chronic masitinib treatment in APPPS1dE9 transgenic mice modeling Alzheimer’s disease. Journal of Alzheimer's Disease, 2020, 76 (4), pp.1339-1345. ⟨10.3233/jad-200466⟩. ⟨hal-03035522⟩
209 Consultations
280 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More